In this context, human serum albumin (HSA), the major serum protein, represents a validated and safe biomaterial that can extend therapeutics half-life and preferentially accumulates within the tumor mass, thereby reducing off-target side-effects [44]. This evidence concerns the gene ALB and neoplasm.